Viray R, Turlapaty P, Laddu A
Department of Clinical Research, Du Pont Critical Care Inc., Waukegan, IL 60085.
Int J Clin Pharmacol Ther Toxicol. 1988 Mar;26(3):153-61.
Esmolol (Brevibloc) is a potent, titratable, cardioselective beta-blocker with a short elimination half-life (t1/2 = 9.2 min) and no intrinsic sympathomimetic activity. It was designed for use in critically ill patients who would benefit from the short duration of beta-adrenergic blockade. Esmolol's short duration of action allows for rapid onset and control of hemodynamic effects. Its safety and efficacy has been demonstrated in patients with acute myocardial ischemia. This review provides a brief summary of the pharmacology of esmolol, as well as experimental and clinical evidence on the use of esmolol in acute myocardial ischemia.
艾司洛尔（Brevibloc）是一种强效、可滴定、心脏选择性β受体阻滞剂，消除半衰期短（t1/2 = 9.2分钟），且无内在拟交感活性。它专为危重症患者设计，这些患者将从短期的β肾上腺素能阻滞中获益。艾司洛尔作用持续时间短，可实现血流动力学效应的快速起效和控制。其安全性和有效性已在急性心肌缺血患者中得到证实。本综述简要总结了艾司洛尔的药理学，以及艾司洛尔在急性心肌缺血中应用的实验和临床证据。
